Abingworth LLP's Form 4 filing
Soleno Therapeutics Inc (SLNO) · filed Mar 31, 2022
- Accession no.
- 0000905718-22-000523
- Filed
- Mar 31, 2022
- Trade date
- Dec 21, 2018-Mar 29, 2022
- Filing delay
- 1,196 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 6 derivative transactions. It was filed 1196 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Abingworth LLPCIK 0001397144 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 29, 2022 | Common Stock | PPurchaseAcquired | +7,720,000 | –F3 | – | 18,022,602 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2018 | Common Stock | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 20,000 | Indirect | |
| Jun 10, 2019 | Common Stock | AGrant or awardAcquired | +13,000 | $0.00 | $0 | 13,000 | Indirect | |
| May 18, 2020 | Common Stock | AGrant or awardAcquired | +9,530 | $0.00 | $0 | 9,530 | Indirect | |
| Jan 8, 2021 | Common Stock | AGrant or awardAcquired | +40,000 | $0.00 | $0 | 40,000 | Indirect | |
| Jun 1, 2021 | Common Stock | AGrant or awardAcquired | +31,862 | $0.00 | $0 | 31,862 | Indirect | |
| Mar 29, 2022 | Common Stock | PPurchaseAcquired | +7,720,000 | –F3 | – | 7,720,000 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.